Home    Back

Vaccine    (DrugBank: -)

1 disease
IDDisease name (Link within this page)Number of trials
49Systemic lupus erythematosus15

49. Systemic lupus erythematosus    [ 827 clinical trials,   638 drugs,   (DrugBank: 168 drugs),   108 drug target genes,   191 drug target pathways]
Searched query = "Systemic lupus erythematosus", "SLE"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
15 / 827 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT04516408
(ClinicalTrials.gov)		October 1, 202013/8/2020Recombinant Zoster Vaccine in Stable SLE PatientsEfficacy and Safety of Recombinant Zoster Vaccine in Stable SLE Patients(Vtrial)Herpes Zoster;Recombinant Zoster Vaccine;Systemic Lupus ErythematosusBiological: Recombinant zoster vaccine;Biological: PlaceboRenJi HospitalNULLNot yet recruiting50 YearsN/AAll464N/ANULL
2NCT03618056
(ClinicalTrials.gov)		December 19, 20181/8/2018Evaluating HIV-1 Neutralization Antibody Breadth in Response to HIV gp120 Protein Vaccine in HIV-uninfected Adults With Quiescent Systemic Lupus ErythematosusA Phase 1b Open Label Clinical Trial to Evaluate HIV-1 Neutralization Antibody Breadth in Response to HIV gp120 Protein Vaccine in HIV-uninfected Adults With Quiescent Systemic Lupus ErythematosusHIV Infections;Systemic Lupus ErythematosusBiological: AIDSVAX® B/ENational Institute of Allergy and Infectious Diseases (NIAID)NULLCompleted18 Years50 YearsAll1Phase 1United States
3NCT02477150
(ClinicalTrials.gov)		November 201517/6/2015Safety and Immunogenicity of a Zoster Vaccine in SLEImmunogenicity and Safety of a Herpes Zoster Vaccine (Zostavax) in Patients With Systemic Lupus Erythematosus: a Randomized Controlled TrialSystemic Lupus ErythematosusBiological: Zostavax;Biological: placeboTuen Mun HospitalNULLCompleted18 YearsN/AAll90Phase 4China
4NCT02477254
(ClinicalTrials.gov)		July 201517/6/2015Long-term Immunogenicity of a HPV Vaccine in SLELong-term Immunogenicity of a Quadrivalent Human Papillomavirus (HPV) Vaccine in Patients With Systemic Lupus Erythematosus: a Case-control StudySystemic Lupus ErythematosusBiological: VaccinationTuen Mun HospitalNULLCompleted18 Years35 YearsFemale84N/AChina
5NCT01741012
(ClinicalTrials.gov)		January 201314/11/2012Study to Determine if Gardasil Vaccine is Safe and Effective in Lupus PatientsPhase I, Safety and Immunogenicity of Gardasil® in Systemic Lupus Erythematosus.Systemic Lupus ErythematosusDrug: GardasilWayne State UniversityMerck Sharp & Dohme Corp.Completed18 Years50 YearsFemale37Phase 1United States
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
6NCT01687192
(ClinicalTrials.gov)		October 201213/9/2012Multicenter Trial Evaluating the Immunogenicity of HPV Vaccination in Girls on Immunosuppressive Therapy.Multicenter Clinical Trial Evaluating the Immunological Response of Vaccination Against Infection by Human Papillomavirus (HPV) 6, 11, 16, 18 in Girls Receiving Immunosuppressive Therapy.Transplantation;Systemic Lupus Erythematosus;Systemic Immune DiseaseBiological: HPV prophylactic vaccine GardasilUniversity Hospital, BordeauxNULLActive, not recruiting9 Years18 YearsFemale37Phase 2France
7NCT01597492
(ClinicalTrials.gov)		May 31, 20128/5/2012A Study to Evaluate the Effect of Belimumab on Vaccine Responses in Subjects With Systemic Lupus Erythematosus (SLE)A Phase 4, Multi-Center, Randomized, Open-Label Study to Evaluate the Effect of BENLYSTA™ (Belimumab; HGS1006) on Vaccine Responses in Subjects With Systemic Lupus Erythematosus (SLE)Systemic Lupus ErythematosusBiological: Belimumab plus Early Vaccination;Biological: Belimumab plus Late VaccinationHuman Genome Sciences Inc., a GSK CompanyGlaxoSmithKlineCompleted18 YearsN/AAll79Phase 4United States
8NCT01474720
(ClinicalTrials.gov)		November 201115/11/2011Zostavax in Systemic Lupus ErythematosusImmunologic Response to Varicella Zoster Vaccination With Zostavax in Patients With Systemic Lupus ErythematosusSystemic Lupus ErythematosusDrug: Zostavax vaccineOklahoma Medical Research FoundationNULLCompleted50 Years75 YearsBoth20Phase 1United States
9NCT01151644
(ClinicalTrials.gov)		April 201025/6/2010Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic DiseasesSafety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic DiseasesRheumatoid Arthritis;Spondyloarthritis;Systemic Lupus Erythematosus (SLE);Dermatomyositis (DM);DMixed Connective Tissue Disease;Systemic Vasculitis;Systemic Sclerosis (SSc);Sjögren's Syndrome;Antiphospholipid Syndrome;Juvenile Idiopathic Arthritis;Juvenile SLE;Juvenile DMBiological: Anti-pandemic H1N1 influenza vaccineUniversity of Sao PauloFundação de Amparo à Pesquisa do Estado de São PauloActive, not recruitingN/AN/ABoth5000Phase 4Brazil
10NCT01006681
(ClinicalTrials.gov)		November 200931/10/2009Vaccination Against Influenza H1N1 in Rheumatic DiseasesEfficacy and Safety of Vaccination Against Influenza H1N1 in Patients With Rheumatoid Arthritis, Systemic Lupus Erythematosus, Psoriatic Arthritis and Ankylosing Spondylitis Treated With Immunomodulatory DrugsInfluenza;Rheumatic DiseasesBiological: Focetria (Monovalent MF59-Adjuvanted vaccine)Tel-Aviv Sourasky Medical CenterNULLNot yet recruiting18 Years65 YearsBoth400Phase 2NULL
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
11NCT00911521
(ClinicalTrials.gov)		October 200928/5/2009Immunogenicity and Safety of a Quadrivalent Human Papillomavirus (HPV) Vaccine in Patients With SLE: a Controlled StudyImmunogenicity and Safety of a Quadrivalent Human Papillomavirus (HPV) Vaccine in Patients With Systemic Lupus Erythematosus (SLE): a Controlled StudySystemic Lupus ErythematosusDrug: human papillomavirus vaccination (Gardasil)Tuen Mun HospitalNULLCompletedN/A35 YearsFemale100Phase 4China
12NCT01072734
(ClinicalTrials.gov)		September 200919/2/2010Auto-immunity in Lupus Patients After Influenza VaccineRole of CXCR4/CXCL12 Axis on the Control of Humoral Immunity and Auto-immunity in Lupus Patients After Influenza Vaccine ChallengeSystemic Lupus Erythematosus (SLE)Drug: VaccineAssistance Publique - Hôpitaux de ParisInstitut National de la Santé Et de la Recherche Médicale, FranceCompleted18 YearsN/ABoth28Phase 2France
13NCT00786409
(ClinicalTrials.gov)		November 20085/11/2008Immunogenicity and Safety of HPV Vaccine Gardasil in Young WomenImmunogenicity and Safety of the Quadrivalent HPV Vaccine Gardasil in Female Systemic Lupus Erythematosus Patients Aged 9-26Systemic Lupus ErythematosusBiological: GardasilUniversity of ChicagoMerck Sharp & Dohme Corp.Completed9 Years26 YearsFemale27N/AUnited States
14NCT00611663
(ClinicalTrials.gov)		May 200828/1/2008Safety Study of Two Vaccine Strategies in Patients With Systemic Lupus ErythematosusVACCILUP A Multicenter, Randomized Double-blind Trial Comparing Two Pneumococcal Vaccination Strategies in Patients With Systemic Lupus ErythematosusLupus Erythematosus, SystemicBiological: Prevenar® and Pneumo23®;Biological: Placebo, Pneumo23®Assistance Publique - Hôpitaux de ParisNULLCompleted18 Years65 YearsBoth47Phase 2;Phase 3France
15EUCTR2007-004579-21-NL
(EUCTR)		27/08/200729/08/2007Does booster influenza vaccination improve vaccination efficacy in patients with quiescent systemic lupus erythematosus?Does booster influenza vaccination improve vaccination efficacy in patients with quiescent systemic lupus erythematosus? systemic lupus erythematosus (SLE)SLE is a systemic autoimmune disease.
MedDRA version: 9.1;Level: LLT;Classification code 10025139;Term: Lupus erythematosus systemic		Trade Name: Influvac
INN or Proposed INN: Influenz virus surface antigens
Other descriptive name: INFLUENZA VACCINE (SURFACE ANTIGEN, INACTIVATED)		University Medical Center GroningenNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes		Netherlands

Back to top